ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study.
Open access · hybridAbstract read
In one paragraph
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
28.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 26 citations in OpenAlex.
- Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study.The Lancet. Neurology · 2025Trial
- Multimodal neuroimaging in dementia and neurodegenerative disorders: complementary roles of clinically available nuclear medicine and MRI in the era of disease-modifying therapies.Japanese journal of radiology · 2026Review
- From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment.European journal of nuclear medicine and molecular imaging · 2026Article
- Plasma Glial Fibrillary Acidic Protein and Neurofilament Light Chain Concentrations Are Inversely Associated with Retinal Microvascular Perfusion and Vessel Density in Cognitively Normal Individuals with Familial or Genetic Risk Factors for Alzheimer's Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease.bioRxiv : the preprint server for biology · 2026Article
- Investigating a relation between amyloid beta plaque burden and accumulated neurotoxicity caused by amyloid beta oligomers.Medical & biological engineering & computing · 2026Article
- The Centiloid Scale in Amyloid PET Imaging: Current Role in Alzheimer's Disease Diagnosis, Treatment Planning, and Monitoring During Anti-Amyloid Therapy: A Clinical Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Imaging and plasma biomarkers for pathological accumulation in Down syndrome.Brain : a journal of neurology · 2026Article
- Precision pathways: optimising amyloid PET for sustainable Alzheimer's disease care.Journal of neurology · 2026Review
- Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study.Alzheimer's research & therapy · 2026Article
- AI-enhanced Centiloid quantification of amyloid PET images.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2026Review
- Exploring Centiloid Robustness: Impact of Sample Size and Image Resolution on Centiloid Conversion Accuracy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Clarifying what BP Predicts: Commentary on CSF Aβ42/40, p-tau181, and centiloid in unimpaired populations.The journal of prevention of Alzheimer's disease · 2025Article
- Complementary utility of plasma biomarkers and Aβ-PET for diagnosis, risk-stratification, and treatment monitoring in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Predicting cognitive decline with amyloid-PET, plasma p-tau217, Aβ42/40, and p-tau217/Aβ42 in a community-based cohort - relevance for clinical trial enrollment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Concordance between Centiloid Quantification and Visual Interpretation of Amyloid PET Scans across the Alzheimer Disease Continuum.AJNR. American journal of neuroradiology · 2025Article
- Comparison and cutoff values of two amyloid PET scaling methods: centiloid scale and amyloid-β load.Annals of nuclear medicine · 2025Article
- Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study.European journal of nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 20 institutions in 9 countries.
Ariane BollackCentre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, London, UK.ORCID 0000-0002-9169-7530
Lyduine E CollijDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.ORCID 0000-0001-6263-1762
David Vállez GarcíaDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.ORCID 0000-0003-3308-3167
Mahnaz ShekariBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.ORCID 0000-0003-1336-6768
Daniele AltomareNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.ORCID 0000-0003-1905-8993
Pierre PayouxDepartment of Nuclear Medicine, Imaging Pole, Toulouse University Hospital, Toulouse, France.
Bruno DuboisDepartment of Neurology, Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.
Oriol Grau-RiveraBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Mercè BoadaAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.ORCID 0000-0003-2617-3009
Marta MarquiéAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.ORCID 0000-0002-0660-0950
Agneta NordbergDepartment of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
Zuzana WalkerDivision of Psychiatry, University College London, London, UK.ORCID 0000-0001-7346-8200
Philip ScheltensAlzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Alzheimercentrum Amsterdam, Amsterdam, The Netherlands.
Michael SchöllWallenberg Centre for Molecular and Translational Medicine, The University of Gothenburg, Gothenburg, Sweden.
Robin WolzIXICO Plc, London, UK.
Jonathan M SchottDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Rossella GismondiLife Molecular Imaging, GmbH, Berlin, Germany.
Andrew StephensLife Molecular Imaging, GmbH, Berlin, Germany.ORCID 0000-0001-5052-6586
Christopher BuckleyGE HealthCare, Buckinghamshire, UK.
Giovanni B FrisoniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Bernard HanseeuwDepartment of Neurology, Institute of Neuroscience, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium.ORCID 0000-0002-3102-6778
Pieter Jelle VisserDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Rik VandenbergheLaboratory for Cognitive Neurology, LBI - KU Leuven Brain Institute, Leuven, Belgium.
Alexander DrzezgaDepartment of Nuclear Medicine, University Hospital Cologne, Universitätsklinikums Köln, Köln, Germany.
Maqsood YaqubDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Ronald BoellaardDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
Juan Domingo GispertBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.ORCID 0000-0002-6155-0642
Pawel MarkiewiczCentre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, London, UK.ORCID 0000-0002-3114-0773
David M CashQueen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0001-7833-616X
Gill FarrarGE HealthCare, Buckinghamshire, UK.
Frederik BarkhofCentre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, London, UK.ORCID 0000-0003-3543-3706
AMYPAD consortium
Amsterdam University Medical Centers · NLBuckinghamshire Healthcare NHS Trust · GBInstituto de Salud Carlos III · ESUK Dementia Research Institute · GBUniversitat Pompeu Fabra · ESUniversity of Brescia · ITAmsterdam Neuroscience · NLCliniques Universitaires Saint-Luc · BEForschungszentrum Jülich · DEIxico (United Kingdom) · GBKarolinska Institutet · SEKarolinska University Hospital · SELondon South Bank University · GBLund University · SENational Hospital for Neurology and Neurosurgery · GBPasqual Maragall Foundation · ESSahlgrenska University Hospital · SESorbonne Université · FRSouth Essex Partnership University Foundation NHS Trust · GBUniversité Toulouse III - Paul Sabatier · FR
Funding
Alzheimer's Disease Data Initiative (ADDI)Department of Health's NIHR- funded Biomedical Research Centre at University College LondonEPSRC-funded UCL Centre for Doctoral Training in Intelligent, Integrated Imaging in Healthcare (i4health) EP/S021930/1GE HealthCareInnovative Medicines Initiative 2 115952NIHR Biomedical Research Centre at UCLH
Abstract
introductionTo support clinical trial designs focused on early interventions, our study determined reliable early amyloid-β (Aβ) accumulation based on Centiloids (CL) in pre-dementia populations.
methodsA total of 1032 participants from the Amyloid Imaging to Prevent Alzheimer's Disease-Prognostic and Natural History Study (AMYPAD-PNHS) and Insight46 who underwent [
resultsReliable accumulation in the PNHS was estimated to occur at >3.0 CL/year. Baseline CL of 16 [12,19] best predicted future Aβ-accumulators. Rates of amyloid accumulation were tracer-independent, lower for APOE ε4 non-carriers, and for subjects with higher levels of education. DISCUSSION: Our results support a 12-20 CL window for inclusion into early secondary prevention studies. Reliable accumulation definition warrants further investigations.
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsPositron-Emission TomographyAgedBenzothiazolesBrainFemaleHumansLongitudinal StudiesMaleMiddle AgedPrognosisStilbenesAmyloid beta-PeptidesAniline CompoundsBenzothiazolesStilbenesAlzheimer'samyloidCentiloidlongitudinal PETquantificationreliable accumulation
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.